336 reports of this reaction
1.7% of all ASENAPINE MALEATE reports
#20 most reported adverse reaction
DYSGEUSIA is the #20 most commonly reported adverse reaction for ASENAPINE MALEATE, manufactured by Allergan, Inc.. There are 336 FDA adverse event reports linking ASENAPINE MALEATE to DYSGEUSIA. This represents approximately 1.7% of all 20,068 adverse event reports for this drug.
Patients taking ASENAPINE MALEATE who experience dysgeusia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSGEUSIA is a less commonly reported adverse event for ASENAPINE MALEATE, but still significant enough to appear in the safety profile.
In addition to dysgeusia, the following adverse reactions have been reported for ASENAPINE MALEATE:
The following drugs have also been linked to dysgeusia in FDA adverse event reports:
DYSGEUSIA has been reported as an adverse event in 336 FDA reports for ASENAPINE MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSGEUSIA accounts for approximately 1.7% of all adverse event reports for ASENAPINE MALEATE, making it a notable side effect.
If you experience dysgeusia while taking ASENAPINE MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.